Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2007

View Archived Issues

LigoCyte studies norovirus vaccine in phase I trial

New therapeutic agents for respiratory disorders disclosed in recent patent literature

Recent Merck and Actelion patents cover novel treatment options for cardiovascular disorders

Novel diagnostic agents disclosed in recent Therapharm patent

Trials reveal efficacy of micafungin against Candida infections

Novel dual PARPalpha/gamma agonists as potential antidiabetics

Novel nonsteroidal glucocorticoid receptor modulators with antiinflammatory and antitumor activity

New data on paliperidone effects in schizophrenia presented

Genaera to focus resources on obesity and asthma programs

Phase II onychomycosis trial of EcoNail completes enrollment

Studies show enhancement of oritavancin activity with polysorbate 80

Enrollment opens in Bronchitol phase III trial for cystic fibrosis

Novosom acquires CD40 inhibitors option from Isis

Xanthus acquires license to patent estate covering FLT3 inhibition

DOR plans clinical program for Lipid Polymer Micelle technology

AlphaVax begins clinical trials for vaccines for CMV and flu

Concerns over link between Xenical and gallstones

VRI plans clinical trials for new anticancer vaccine

Glivec shows recurrence-free survival advantage as adjuvant treatment for GIST

NP-61 to begin clinical testing for Alzheimer's

Anti-CD44 MAb from Arius shows potential in liver cancer

Food effects on the pharmacokinetics of PD-325901 in humans

Novel transcription inhibitor reduces VEGF levels in patients

Next-generation taxane crosses the blood-brain barrier and is active against brain tumors

MB-07133 safe and active in an ongoing clinical study in patients with liver cancer

FDA approves new dose of Risperdal Consta for schizophrenia

Requip XL 24-Hour Extended-Release Tablets accepted for review

Satraplatin NDA accepted for priority review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...